Dr. Mark W. Ornstein

Internal Medicine
Office
4 Industrial Way W Fl 2, 
Eatontown, NJ 
Office
4 Industrial Way W Fl 2, 
Eatontown, NJ 

Overview

Mark Ornstein is a primary care provider, practicing in Internal Medicine in Eatontown, New Jersey.

His clinical expertise encompasses Alzheimer's Disease, Dementia, Unverricht-Lundborg Syndrome, and Lafora Disease.

He is actively involved in clinical research, co-authoring 1 peer reviewed article and participating in 7 clinical trials.

Specialties

Internal Medicine

Licenses

Internal Medicine in NJ

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Cigna
  • EPO
  • HMO
  • PPO
Horizon Healthcare
  • EPO
  • POS
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO

Locations

Office
4 Industrial Way W Fl 2, Eatontown, NJ 07724

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

A Phase 2 Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of AL002 in Participants With Early Alzheimer's Disease
A Phase 2 Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of AL002 in Participants With Early Alzheimer's Disease
Enrollment Status: Completed
Publish Date: October 29, 2025
Intervention Type: Drug
Study Drug: AL002
Study Phase: Phase 2
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Study Evaluating the Safety and Efficacy of Simufilam 100 mg Tablets in Subjects With Mild-to-Moderate Alzheimer's Disease
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Study Evaluating the Safety and Efficacy of Simufilam 100 mg Tablets in Subjects With Mild-to-Moderate Alzheimer's Disease
Enrollment Status: Completed
Publish Date: May 25, 2025
Intervention Type: Drug
Study Drug: Simufilam
Study Phase: Phase 3
A Phase 2A Study to Evaluate Safety, Tolerability and Pharmacological Effects of PU AD in Subjects With Mild Alzheimer's Disease (AD) Dementia
A Phase 2A Study to Evaluate Safety, Tolerability and Pharmacological Effects of PU AD in Subjects With Mild Alzheimer's Disease (AD) Dementia
Enrollment Status: Terminated
Publish Date: November 17, 2022
Intervention Type: Radiation, Behavioral, Diagnostic test, Drug
Study Drug: Dihydrochloride Salt
Study Phase: Phase 2
Effect of LY3202626 on Alzheimer's Disease Progression as Measured by Cerebral ¹⁸F-AV-1451 Tau-PET in Mild Alzheimer's Disease Dementia
Effect of LY3202626 on Alzheimer's Disease Progression as Measured by Cerebral ¹⁸F-AV-1451 Tau-PET in Mild Alzheimer's Disease Dementia
Enrollment Status: Terminated
Publish Date: April 19, 2021
Intervention Type: Drug
Study Phase: Phase 2
A Randomized, Double-Blind, Delayed-Start Study of LY3314814 (AZD3293) in Early Alzheimer's Disease Dementia (Extension of Study AZES, The AMARANTH Study)
A Randomized, Double-Blind, Delayed-Start Study of LY3314814 (AZD3293) in Early Alzheimer's Disease Dementia (Extension of Study AZES, The AMARANTH Study)
Enrollment Status: Terminated
Publish Date: December 03, 2019
Intervention Type: Drug
Study Phase: Phase 3
A 24-month, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Efficacy, Safety, Tolerability, Biomarker, and Pharmacokinetic Study of AZD3293 in Early Alzheimer's Disease (The AMARANTH Study)
A 24-month, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Efficacy, Safety, Tolerability, Biomarker, and Pharmacokinetic Study of AZD3293 in Early Alzheimer's Disease (The AMARANTH Study)
Enrollment Status: Terminated
Publish Date: December 03, 2019
Intervention Type: Drug
Study Phase: Phase 2/Phase 3
A 24-Month, Phase 3, Multicenter, Placebo-Controlled Study of Efficacy and Safety of Solanezumab Versus Placebo in Prodromal Alzheimer's Disease
A 24-Month, Phase 3, Multicenter, Placebo-Controlled Study of Efficacy and Safety of Solanezumab Versus Placebo in Prodromal Alzheimer's Disease
Enrollment Status: Terminated
Publish Date: October 10, 2019
Intervention Type: Drug
Study Phase: Phase 3
View 6 Less Clinical Trials

1 Total Publications

Role of Tau Acetylation in Alzheimer's Disease and Chronic Traumatic Encephalopathy: The Way Forward for Successful Treatment.
Role of Tau Acetylation in Alzheimer's Disease and Chronic Traumatic Encephalopathy: The Way Forward for Successful Treatment.
Journal: Journal of neurology and neurosurgery
Published: December 26, 2017
Similar Doctors
Expertise in
39
conditions
Dr. Mark G. Lebwohl
Internal Medicine
Expertise in
39
conditions
Dr. Mark G. Lebwohl
Internal Medicine
Before you request

Icahn School Of Medicine At Mount Sinai

5 E 98th St, 
New York, NY 
 (34.5 miles away)
212-241-9728
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Mark Lebwohl is a primary care provider, practicing in Internal Medicine in New York, New York. Dr. Lebwohl is highly rated in 39 conditions, according to our data. His clinical expertise encompasses Plaque Psoriasis, Psoriasis, Pustular Psoriasis, and Generalized Pustular Psoriasis (GPP). Dr. Lebwohl is currently accepting new patients.

Expertise in
61
conditions
Dr. Marco Tartaglia
Internal Medicine
Expertise in
61
conditions
Dr. Marco Tartaglia
Internal Medicine

Orthopedic Specialist Group

20 Watsessing Ave, 
Bloomfield, NJ 
 (34.2 miles away)
973-364-0888
Languages Spoken:
English

Marco Tartaglia is a primary care provider, practicing in Internal Medicine in Bloomfield, New Jersey. Dr. Tartaglia is highly rated in 61 conditions, according to our data. His clinical expertise encompasses RASopathies, Noonan Syndrome, Rommen Mueller Sybert Syndrome, and Cardiomyopathic Lentiginosis.

Expertise in
13
conditions
Dr. Ryan C. Ungaro
Internal Medicine
Expertise in
13
conditions
Dr. Ryan C. Ungaro
Internal Medicine

MSSM-Optical Shop

17 E 102nd St, 
New York, NY 
 (34.7 miles away)
212-241-8100
Experience:
17+ years
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Ryan Ungaro is a primary care provider, practicing in Internal Medicine in New York, New York. He has been practicing medicine for over 17 years. Dr. Ungaro is highly rated in 13 conditions, according to our data. His clinical expertise encompasses Crohn's Disease, Viral Gastroenteritis, Ulcerative Colitis, Colonoscopy, and Endoscopy.

Frequently Asked Questions about Dr. Mark W. Ornstein

How do I make an appointment with Dr. Mark W. Ornstein?

You can book an appointment with Dr. Mark W. Ornstein by calling their office at 732-263-0101. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Mark W. Ornstein a top-rated expert for Alzheimer's Disease?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Mark W. Ornstein is classified as an Experienced expert for Alzheimer's Disease, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Mark W. Ornstein specialize in?

While Dr. Mark W. Ornstein is a Internal Medicine, they have specific expertise in Alzheimer's Disease, Dementia, and Unverricht-Lundborg Syndrome. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Internal Medicine.

Does Dr. Mark W. Ornstein participate in research or clinical trials?

Yes. Dr. Mark W. Ornstein has published 1 articles and abstracts on conditions like Alzheimer's Disease. You can view a list of Dr. Mark W. Ornstein's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Mark W. Ornstein accept my insurance?

Dr. Mark W. Ornstein accepts most major insurance plans, including Cigna and Horizon Healthcare. We recommend calling the office directly at 732-263-0101 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Ornstein's expertise for a condition
ConditionClose
        View All 7 Experienced Conditions
        Want to save this doctor for later?
        Sign Up
        Is this your doctor?
        Find A Second Opinion
        Not sure about your diagnosis?
        Check Your Symptoms
         
         
         
         
        Learn about our expert tiers
        Learn More
        Are you the provider on this profile?
        Claim Profile